Access Bio Inc
Korea ExchangeTotal Valuation
Access Bio Inc carries a market capitalization of - -, placing it among publicly traded companies globally. Its enterprise value stands at -331.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | - - |
| Enterprise Value | -331.58B |
Financial Position
Access Bio Inc maintains a current ratio of 16.86, meaning it holds 16.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.65, indicating elevated leverage, while an interest coverage ratio of -32.34 demonstrates limited ability to service its debt obligations.
| Current Ratio | 16.86 |
| Quick Ratio | 15.09 |
| Debt / Equity | 7.65 |
| Debt / EBITDA | -0.65 |
| Interest Coverage | -32.34 |
Financial Efficiency
| Return on Equity (ROE) | -13.73 |
| Return on Assets (ROA) | -12.45 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.23 |
Taxes
| Income Tax | -24.80B |
| Effective Tax Rate | N/A |
Stock Price Statistics
Access Bio Inc's stock has declined approximately -1.84332% over the past 52 weeks. The 50-day moving average sits at 5,639.00, while the 200-day moving average is 6,439.85.
| Beta (5Y) | N/A |
| 52-Week Price Change | -1.84332% |
| 50-Day Moving Average | 5,639.00 |
| 200-Day Moving Average | 6,439.85 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Access Bio Inc generated 15.55B in revenue and converted that into -83.46B in net income, yielding earnings per share of -2,418.27. EBITDA reached -66.76B, while operating income came in at -66.76B.
| Revenue | 15.55B |
| Gross Profit | -33.40B |
| Operating Income | -66.76B |
| Pretax Income | -109.13B |
| Net Income | -83.46B |
| EBITDA | -66.76B |
| EBIT | -66.76B |
| Earnings Per Share (EPS) | -2,418.27 |
Balance Sheet
Access Bio Inc holds 376.46B in cash and equivalents against 43.70B in total debt, resulting in a net debt position of -281.57B. Total book value stands at 573.86B, with working capital of 395.69B providing operational flexibility.
| Cash & Cash Equivalents | 376.46B |
| Total Debt | 43.70B |
| Net Debt | -281.57B |
| Equity (Book Value) | 573.86B |
| Book Value Per Share | 16,455.24 |
| Working Capital | 395.69B |
Cash Flow
Access Bio Inc produced -70.60B in operating cash flow over the past twelve months. After subtracting -1.50B in capital expenditures, free cash flow totaled -72.10B - equivalent to -2,067.42 per share.
| Operating Cash Flow | -70.60B |
| Capital Expenditures | -1.50B |
| Free Cash Flow | -72.10B |
| FCF Per Share | -2,067.42 |
Margins
Access Bio Inc operates with a gross margin of -214.79, reflecting its pricing power and cost economics. The operating margin of -429.37 and net profit margin of -536.74 provide insight into operational efficiency.
| Gross Margin | -214.79 |
| Operating Margin | -429.37 |
| Pretax Margin | -701.85 |
| Profit Margin | -536.74 |
| EBITDA Margin | -429.37 |
Scores
Access Bio Inc posts an Altman Z-Score of 1.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.72 |